Literature DB >> 11092288

Type 2 diabetes: incremental medical care costs during the 8 years preceding diagnosis.

G A Nichols1, H S Glauber, J B Brown.   

Abstract

OBJECTIVE: To describe and analyze medical care costs for the 8 years preceding a diagnosis of type 2 diabetes. RESEARCH DESIGN AND METHODS: From electronic records of a large group-model health maintenance organization (HMO), we ascertained the medical care costs preceding diagnosis for all members with type 2 diabetes who were newly diagnosed between 1988 and 1995. To isolate incremental costs (costs caused by the future diagnosis of diabetes), we subtracted the costs of individually age- and sex-matched HMO members without impending diabetes from the costs of members who were destined to receive this diagnosis. We also compared these prediagnosis costs with the first 3 years of postdiagnosis costs.
RESULTS: An economic burden from impending diabetes is apparent for at least 8 years before diagnosis, beginning with costs for outpatient and pharmacy services. Diabetes-associated incremental costs (costs of type 2 diabetic patients minus matched costs of nondiabetic patients) averaged $1,205 per type 2 diabetic patient per year during the first eight prediagnostic years, including $1,913 each year for the 3 years preceding diagnosis. In the year immediately preceding diagnosis, incremental costs were equivalent to those observed in the second and third years after diagnosis.
CONCLUSIONS: Incremental costs of diabetes begin at least 8 years before diagnosis and grow at an accelerating rate as diagnosis approaches and immediately after diagnosis. These incremental costs span the full range of medical services. Furthermore, the majority of these costs are for conditions not normally associated with diabetes or its complications.

Entities:  

Mesh:

Year:  2000        PMID: 11092288     DOI: 10.2337/diacare.23.11.1654

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  20 in total

Review 1.  [Genetics of type 2 diabetes].

Authors:  Y Böttcher; P Kovacs; A Tönjes; M Stumvoll
Journal:  Internist (Berl)       Date:  2005-07       Impact factor: 0.743

Review 2.  The economics of diabetes prevention.

Authors:  William H Herman
Journal:  Med Clin North Am       Date:  2011-03       Impact factor: 5.456

3.  Metabolic syndrome components are associated with future medical costs independent of cardiovascular hospitalization and incident diabetes.

Authors:  Gregory A Nichols; Edward J Moler
Journal:  Metab Syndr Relat Disord       Date:  2010-12-18       Impact factor: 1.894

4.  Higher medical care costs accompany impaired fasting glucose.

Authors:  Gregory A Nichols; Jonathan B Brown
Journal:  Diabetes Care       Date:  2005-09       Impact factor: 19.112

5.  Increased cardiovascular disease, resource use, and costs before the clinical diagnosis of diabetes in veterans in the southeastern U.S.

Authors:  Darin E Olson; Ming Zhu; Qi Long; Diana Barb; Jeehea S Haw; Mary K Rhee; Arun V Mohan; Phyllis I Watson-Williams; Sandra L Jackson; Anne M Tomolo; Peter W F Wilson; K M Venkat Narayan; Joseph Lipscomb; Lawrence S Phillips
Journal:  J Gen Intern Med       Date:  2015-01-22       Impact factor: 5.128

6.  Trajectory of Excess Medical Expenditures 10 Years Before and After Diabetes Diagnosis Among U.S. Adults Aged 25-64 Years, 2001-2013.

Authors:  Sundar S Shrestha; Ping Zhang; Israel A Hora; Edward W Gregg
Journal:  Diabetes Care       Date:  2018-11-19       Impact factor: 19.112

7.  Random plasma glucose in serendipitous screening for glucose intolerance: screening for impaired glucose tolerance study 2.

Authors:  David C Ziemer; Paul Kolm; Jovonne K Foster; William S Weintraub; Viola Vaccarino; Mary K Rhee; Rincy M Varughese; Circe W Tsui; David D Koch; Jennifer G Twombly; K M Venkat Narayan; Lawrence S Phillips
Journal:  J Gen Intern Med       Date:  2008-03-12       Impact factor: 5.128

8.  The Economic Burden of Obesity by Glycemic Stage in the United States.

Authors:  Qian Li; Steven W Blume; Joanna C Huang; Mette Hammer; Thomas R Graf
Journal:  Pharmacoeconomics       Date:  2015-07       Impact factor: 4.981

9.  Osteoporosis and type 2 diabetes mellitus: what do we know, and what we can do?

Authors:  Shaymaa Abdalwahed Abdulameer; Syed Azhar Syed Sulaiman; Mohamed Azmi Ahmad Hassali; Karuppiah Subramaniam; Mohanad Naji Sahib
Journal:  Patient Prefer Adherence       Date:  2012-06-11       Impact factor: 2.711

10.  Nationally representative medical costs of diabetes by time since diagnosis.

Authors:  Justin G Trogdon; Thomas Hylands
Journal:  Diabetes Care       Date:  2008-12       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.